Company profile
ODYSSEY THERAPEUTICS, INC.
NASDAQ:ODTXBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06206811 | phase1 | completed | 2024-02-12 | 2024-11-25 | Odyssey Therapeutics, Inc. | Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants |
| NCT06850727 | phase2 | recruiting | 2025-06-02 | 2026-04-01 | Odyssey Therapeutics, Inc. | Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis |
FDA applications (0)
No records yet.